Different immunological requirements for protection against acute versus persistent friend retrovirus infections

Virology

Volumn 272, Issue 1, 2000, Pages 177-182

  Dittmer, Ulf ^a   Hasenkrug, Kim J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; LIVE VACCINE; NEUTRALIZING ANTIBODY;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; FRIEND LEUKEMIA VIRUS; INFECTION PREVENTION; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; RETROVIRUS INFECTION; SUPPRESSOR CELL; VIRUS NEUTRALIZATION;

ANIMALIA; FRIEND MURINE LEUKEMIA VIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0034691191     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2000.0356     Document Type: Article

References (39)

1. Baba T. W., Jeong Y. S., Pennick D., Bronson R., Greene M. F., Ruprecht R. M. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques [see comments]. Science. 267:1995;1820-1825.
2. Baba T. W., Liska V., Khimani A. H., Ray N. B., Dailey P. J., Penninck D., Bronson R., Greene M. F., McClure H. M., Martin L. N., Ruprecht R. M. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat. Med. 5:1999;194-203.
3. Berkhout B., Verhoef K., van Wamel J. L., Back N. K. Genetic instability of live, attenuated human immunodeficiency virus type 1 vaccine strains. J. Virol. 73:1999;1138-1145.
4. Britt W. J., Chesebro B. Use of monoclonal anti-gp70 antibodies to mimic the effects of the Rfv-3 gene in mice with Friend virus-induced leukemia. J. Immunol. 130:1983;2363-2367.
5. Chesebro B., Bloom M., Wehrly K., Nishio J. Persistence of infectious Friend virus in spleens of mice after spontaneous recovery from virus-induced erythroleukemia. J. Virol. 32:1979;832-837.
6. Chesebro B., Britt W., Evans L., Wehrly K., Nishio J., Cloyd M. Characterization of monoclonal antibodies reactive with murine leukemia viruses: use in analysis of strains of Friend MCF and Friend ecotropic murine leukemia virus. Virology. 127:1983;134-148.
7. Chesebro B., Wehrly K., Cloyd M., Britt W., Portis J., Collins J., Nishio J. Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: Friend-specific and FMR-specific antigens. Virology. 112:1981;131-144.
8. Chesebro B., Wehrly K., Stimpfling J. Host genetic control of recovery from Friend leukemia virus-induced splenomegaly: Mapping of a gene within the major histocompatibility complex. J. Exp. Med. 140:1974;1457-1467.
9. Chun T. W., Engel D., Berrey M. M., Shea T., Corey L., Fauci A. S. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc. Natl. Acad. Sci. USA. 95:1998;8869-8873.
10. Chun T. W., Stuyver L., Mizell S. B., Ehler L. A., Mican J. A., Baseler M., Lloyd A. L., Nowak M. A., Fauci A. S. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA. 94:1997;13193-133197.
11. Ciurea A., Klenerman P., Hunziker L., Horvath E., Odermatt B., Ochsenbein A. F., Hengartner H., Zinkernagel R. M. Persistence of lymphocytic choriomeningitis virus at very low levels in immune mice [In Process Citation]. Proc. Natl. Acad. Sci. USA. 96:1999;11964-11969.
12. Cobbold S. P., Jayasuriya A., Nash A., Prospero T. D., Waldmann H. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature. 312:1984;548-551.
13. Cohen J. Weakened SIV vaccine still kills [news]. Science. 278:1997;24-25.
14. Dittmer U. Live HIV vaccines: How safe? Nat. Med. 3:1997.
15. Dittmer U., Brooks D. M., Hasenkrug K. J. Characterization of a live-attenuated retroviral vaccine demonstrates protection via immune mechanisms. J. Virol. 72:1998;6554-6558.
16. Dittmer U., Brooks D. M., Hasenkrug K. J. Protection against establishment of retroviral persistence by vaccination with a live attenuated virus. J. Virol. 73:1999a.
17. Dittmer U., Brooks D. M., Hasenkrug K. J. Requirement for multiple lymphocyte subsets in protection against retroviral infection by a live attenuated vaccine. Nat. Med. 5:1999b;189-193.
18. Dittmer U., Race B., Hasenkrug K. J. Kinetics of the development of protective immunity in mice vaccinated with a live-attenuated retrovirus. J. Virol. 73:1999c;8435-8440.
19. Finzi D., Hermankova M., Pierson T., Carruth L. M., Buck C., Chaisson R. E., Quinn T. C., Chadwick K., Margolick J., Brookmeyer R., Gallant J., Markowitz M., Ho D. D., Richman D. D., Siliciano R. F. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy [see comments]. Science. 278:1997;1295-1300.
20. Hasenkrug K. J., Brooks D. M., Chesebro B. Passive immunotherapy for retroviral disease: Influence of major histocompatibility complex type and T-cell responsiveness. Proc. Natl. Acad. Sci. USA. 92:1995;10492-10495.
21. + T cells in controlling retrovirus replication and spread in persistently infected mice. J. Virol. 72:1998a;6559-6564.
22. Hasenkrug K. J., Brooks D. M., Nishio J., Chesebro B. Differing T-cell requirements for recombinant retrovirus vaccines. J. Virol. 70:1996;368-372.
23. Hasenkrug K. J., Brooks D. M., Robertson M. N., Srinivas R. V., Chesebro B. Immunoprotective determinants in Friend murine leukemia virus envelop protein. Virology. 248:1998b;66-73.
24. Hoatlin M. E., Kabat D. Host-range control of a retroviral disease: Friend erythroleukemia. Trends Microbiol. 3:1995;51-57.
25. Igarashi T., Brown C., Azadegan A., Haigwood N., Dimitrov D., Martin M. A., Shibata R. Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nat. Med. 5:1999;211-216.
26. Kabat D. Molecular biology of Friend viral erythroleukemia. Curr. Top. Microbiol. Immunol. 148:1989;1-42.
27. Li J.-P., D'Andrea A. D., Lodish H. F., Baltimore D. Activation of cell growth by binding of Friend spleen focus-forming virus gp55 glycoprotein to the erythropoietin receptor. Nature. 343:1990;762-764.
28. Mellors J. W., Rinaldo C. R. Jr., Gupta P., White R. M., Todd J. A., Kingsley L. A. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma [see comments] [published erratum appears in Science (1997) 275, 14]. Science. 272:1996;1167-1170.
29. Moore J. P., Burton D. R. HIV-1 neutralizing antibodies: How full is the bottle? [news]. Nat. Med. 5:1999;142-144.
30. Moreau-Gachelin F., Tavitian A., Tambourin P. Spi-1 is a putative oncogene in virally induced murine erythroleukemia. Nature. 331:1988;277-280.
31. Munroe D. G., Peacock J. W., Benchimol S. Inactivation of the cellular p53 gene is a common feature of Friend virus-induced erythroleukemia: relationship of inactivation to dominant transforming alleles. Mol. Cell. Biol. 10:1990;3307-3313.
32. Oldstone M. B., Tishon A., Eddleston M., de la Torre J. C., McKee T., Whitton J. L. Vaccination to prevent persistent viral infection. J. Virol. 67:1993;4372-4378.
33. Planz O., Ehl S., Furrer E., Horvath E., Brundler M. A., Hengartner H., Zinkernagel R. M. A critical role for neutralizing-antibody-producing B cells, CD4(+) T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: Implications for adoptive immunotherapy of virus carriers. Proc. Natl. Acad. Sci. USA. 94:1997;6874-6879.
34. Poignard P., Sabbe R., Picchio G. R., Wang M., Gulizia R. J., Katinger H., Parren P. W., Mosier D. E., Burton D. R. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity. 10:1999;431-438.
35. Shibata R., Igarashi T., Haigwood N., Buckler-White A., Ogert R., Ross W., Willey R., Cho M. W., Martin M. A. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5:1999;204-210.
36. Sitbon M., Nishio J., Wehrly K., Lodmell D., Chesebro B. Use of a focal immunofluorescence assay on live cells for quantitation of retroviruses: Distinction of host range classes in virus mixtures and biological cloning of dual-tropic murine leukemia viruses. Virology. 141:1985;110-118.
37. Slifka M. K., Antia R., Whitmire J. K., Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity. 8:1998;363-372.
38. + T cells in the Friend murine retrovirus neutralizing antibody response: Evidence for functional T cells in genetic low-recovery mice. J. Virol. 72:1998;9400-9403.
39. Wendling F., Tambourin P. E. Oncogenicity of Friend-virus-infected cells: Determination of origin of spleen colonies by the H-2 antigens as genetic markers. Int. J. Cancer. 22:1978;479-486.